Three weeks after University of Washington biochemist David Baker won a Nobel Prize, the latest venture to spin out from his lab — Archon Biosciences — has emerged from stealth mode with $20 million in financing for a technology that uses computationally designed protein structures to treat cancer and other diseases.
The seed funding round was led by Madrona Ventures, with participation from DUMAC Inc., Sahsen Ventures, WRF Capital, Pack Ventures, Alexandria Venture Investments and Cornucopian Capital.
Archon’s proprietary protein structures, known as Antibody Cages or AbCs, have been years in the making. Archon’s CEO and co-founder, James Lazarovits, said the Nobel Prize that Baker won for his pioneering work in the field of protein design confirms his view that the newly unveiled startup is on the right track.
“It’s reaffirmed our conviction for why we’re in this place to begin with,” Lazarovits told me during a tour of Archon’s Seattle lab. “It’s doing things that were not possible before. … You could not do anything that we’re doing unless there was the convergence of all these different fields at this moment in time.”

